公开(公告)号：US20170360783A1

公开(公告)日：2017-12-21

申请号：US15693963

申请日：2017-09-01

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Emily O. Dumas ,  Bo Fu ,  Abhishek Gulati ,  Yiran Bonnie Hu ,  Jens Kort ,  Matthew Kosloski ,  Preethi Krishnan ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Federico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Susan Rhee ,  Nancy S. Shulman ,  Roger Trinh ,  Rolado M. Viani ,  Stanley Wang ,  Zhenzhen Zhang

IPC: A61K31/4985 ,  A61K31/454

CPC classification number: A61K31/4985 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20150209403A1

公开(公告)日：2015-07-30

申请号：US14606369

申请日：2015-01-27

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Prajakta Badri ,  Daniel E. Cohen ,  Sandeep Dutta ,  Amit Khatri ,  Rajeev M. Menon ,  Thomas Podsadecki ,  Akshanth Polepally ,  Roger Trinh ,  Tianli Wang ,  Jiuhong Zha

IPC: A61K38/06 ,  A61K38/05 ,  A61K45/06 ,  A61K31/513

CPC classification number: A61K38/06 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/496 ,  A61K31/497 ,  A61K31/513 ,  A61K31/55 ,  A61K38/05 ,  A61K45/06 ,  C07K5/0804 ,  A61K2300/00

Abstract: This application features dose adjustment for drugs co-administered with Compound 1, Compound 2 and/or Compound 3.

Abstract translation: 本申请对与化合物1，化合物2和/或化合物3共同施用的药物具有剂量调整。

公开(公告)号：US20200222397A1

公开(公告)日：2020-07-16

申请号：US16635813

申请日：2018-07-20

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Bo Fu ,  Abhishek Gulati ,  Jens Kort ,  Matthew Kosloski ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Federico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Nancy S. Shulman ,  Roger Trinh ,  Rolando M. Viani ,  Stanley Wang ,  Zhenzhen Zhang

IPC: A61K31/4985 ,  A61K31/454 ,  A61K31/7072 ,  A61K31/498

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240082245A1

公开(公告)日：2024-03-14

申请号：US18386725

申请日：2023-11-03

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Bo Fu ,  Abhishek Gulati ,  Jens Kort ,  Matthew Kosloski ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Federico Mensa ,  Iok Chan NG ,  Tami Pilot-Matias ,  David Pugatch ,  Nancy S. Shulman ,  Roger Trinh ,  Rolando M. Viani ,  Stanley Wang ,  Zhenzhen Zhang

IPC: A61K31/4985 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072

CPC classification number: A61K31/4985 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20200368229A9

公开(公告)日：2020-11-26

申请号：US15667212

申请日：2017-08-02

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Bo Fu ,  Abhishek Gulati ,  Jens Kort ,  Matthew Kosloski ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Federico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Nancy S. Shulman ,  Roger Trinh ,  Rolando M. Viani ,  Stanley Wang ,  Zhenzhen Zhang

IPC: A61K31/4985 ,  A61K31/454

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20200330460A1

公开(公告)日：2020-10-22

申请号：US16643069

申请日：2018-08-30

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Emily O. Dumas ,  Bo Fu ,  Abhishek Gulati ,  Yiran Bonnie Hu ,  Jens Kort ,  Matthew Kosloski ,  Preethi Krishnan ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Frederico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Susan Rhee ,  Nancy S. Shulman ,  Roger Trinh ,  Rolando M. Viani ,  Stanley Wang ,  Zhenzhan Zhang

IPC: A61K31/4985 ,  A61K31/454 ,  A61K31/7072 ,  A61K31/498

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20180042982A1

公开(公告)日：2018-02-15

申请号：US15782162

申请日：2017-10-12

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Tami Pilot-Matias ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Lino Rodrigues Junior ,  Suvajit Samanti ,  Roger Trinh ,  Tianli Wang ,  Betty B. Yao

IPC: A61K38/06 ,  A61K31/7072 ,  A61K31/4184 ,  A61K31/7056

CPC classification number: A61K38/06 ,  A61K31/4184 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K2300/00

Abstract: The present invention generally features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16, 12 or 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. Further, additional compounds such as sofosbuvir, or its pharmaceutically acceptable salt may be used for retreatment of HCV patients who have failed glecaprevir and pibrentasvir combination therapy.